| Jul 8 |
Kymera announces expansion of KT-474 HS and AD phase 2 studies
|
| Jul 8 |
Kymera Announces Expansion of KT-474 (SAR444656) HS and AD Phase 2 Studies Following Interim Review of Safety and Efficacy
|
| Jun 14 |
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
|
| Jun 1 |
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
|
| May 29 |
Kymera Therapeutics to Participate in Upcoming June Investor Conferences
|
| May 24 |
Demystifying Kymera Therapeutics: Insights From 5 Analyst Reviews
|
| May 23 |
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
|
| May 22 |
Kymera Therapeutics Presents New Preclinical Data for KT-621, a First-In-Class, Oral STAT6 Degrader at the ATS Annual Meeting
|
